Trial Profile
A study of Sorafenib and Bavituximab plus Stereotactic Body Radiation Therapy (SBRT) for unresectable hepatitis C associated hepatocellular carcinoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 15 Oct 2018 Status changed from recruiting to withdrawn prior to enrolment due to loss in interest. Investigator was unable to enroll any participants on study
- 17 Jan 2018 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
- 07 Sep 2017 According to a Peregrine Pharmaceuticals media release, National Comprehensive Cancer Network (NCCN) is responsible for oversight and monitoring of this and other two clinical studies (CTP700276383 and CTP276389) through the research grant.